FIELD: chemistry.
SUBSTANCE: antibodies and antigen binding fragments thereof are described, that bind an extracellular domain of HER3 receptor and inhibit various functions associated with HER3 receptor by means of a ligand-dependent and/or ligand-independent mechanism. The compositions with increased half-life are represented as well. Furthermore, invention relates to compositions and methods for diagnosis and treatment of diseases associated with HER3-mediated signal transduction.
EFFECT: invention expands the arsenal of diagnostic tools and treatment of diseases associated with HER3-mediated signal transduction.
23 cl, 37 dwg, 7 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO HER3 AND APPLICATION THEREOF | 2010 |
|
RU2560583C2 |
| THERAPY OF MALIGNANT TUMOR, RESISTANT TO PLATINUM-BASED MEDICATIONS | 2005 |
|
RU2403065C2 |
| BISPECIFIC ANTI-HER2 / ANTI-HER3 ANTIBODIES | 2016 |
|
RU2653443C2 |
| COMPOSITION CONTAINING ANTIBODY BINDING TO DOMAIN II OF HER2, AND ITS ACIDIC VERSIONS | 2009 |
|
RU2543664C2 |
| BINDING MOLECULES SPECIFIC TO IL-21, AND FIELD OF APPLICATION THEREOF | 2015 |
|
RU2708336C2 |
| MULTISPECIFIC ANTIBODIES, THEREOF ANALOGUES, COMPOSITIONS AND METHODS | 2010 |
|
RU2580038C2 |
| ANTIBODIES, CAPABLE OF SPECIFIC CONNECTING WITH HER2 | 2014 |
|
RU2628094C2 |
| INTRODUCTION OF FIXED DOSES OF HER-ANTIBODIES | 2005 |
|
RU2438705C2 |
| USE OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE IN THE TREATMENT OF UROTHELIAL CARCINOMA | 2019 |
|
RU2750817C1 |
| COMPOSITION OF HER2 ANTIBODIES | 2005 |
|
RU2361880C2 |
